The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.

COI Statement

Declaration of interests SZ reports grants from Abbott Vascular and personal fees from Novartis and Boston Scientific. JHW reports grants from the American Heart Association and National Institutes of Health; consulting fees from the Institute for Clinical and Economic Review, Pfizer, and Patient Centered Outcomes Research Institute; personal fees from Huff Powell Bailey; support for attending meetings and travel from the American College of Cardiology; and has a leadership and fiduciary role with the New England Comparative Effectiveness Public Affairs Council. VK reports support from Queen Mary University. BZ reports support from the David Geffen School of Medicine and VA Greater Los Angeles Healthcare System; grants from the National Institutes of Health, Veterans Administration, and American Heart Association; and personal fees from the Heart Failure Society of America, Circulation: Cardiovascular Quality and Outcomes, and Scholars in Medicine. WAP reports a leadership and fiduciary role within the Cardiac Society of Australia and New Zealand. TJAC reports support for attending meetings and travel from the University of Sheffield, British Heart Foundation Data Science Centre, and the estate of Mrs Reena Dyer. DCa reports consulting fees from Abbott Vascular; personal fees from Terumo, Sanofi Aventis, NovoNordisk, and Medtronic; and board participation for MedAlliance. NRS reports support for attending meetings and travel from Vanderbilt University Medical Center (for the submitted work); support from Society for Cardiovascular Angiography and Interventions and Zoll (outside the submitted work); grants from the National Institutes of Health, Society for Cardiovascular Angiography and Interventions, and Shockwave; personal fees from Philips, Abbott, Zoll, and Youman & Caputo; has a leadership role with the Women in Innovations Committee and the Society for Cardiovascular Angiography and Interventions; has stock options in Stallion Catheter; and stipend for serving as an associate editor for the Journal of the American Heart Association. RS reports grants from the National Institute for Health and Care Research and participation on a board for the UK Longitudinal Linkage Consortium. DCh reports personal fees from SpectraWave Medical Imaging. NG reports grant support from Abbott; personal fees from Abbott, ShockWave, Abiomed, Philips, and Boston Scientific; board participation for Boston Scientific and Abbott; and a leadership role with the European Association of Percutaneous Cardiovascular Interventions Scientific Documents Committee. SRM reports grant support from Abbott; personal fees from Amgen, Bristol Myers Squibb, Novartis, NovoNordisk, and Janssen; and board participation for Merck. JS reports stock in Anagram Kommunikation and Symptoms Europe. SJN reports grants from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Cyclarity, Eli Lilly, Esperion, Resverlogix, New Amsterdam Pharma, Novartis, InfraReDx, and Sanofi-Regeneron; personal fees from Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, Vaxxinity, Sequiris, and NovoNordisk; is listed as inventor on the patent for effects of PCSK9 inhibition on coronary atherosclerosis; has a leadership and fiduciary role with Cardiac Society of Australia and New Zealand; and is director of Evidence to Practice (non-profit meeting company). LJS reports a leadership and fiduciary role with the Society of Cardiovascular Computed Tomography and that HeartFlow granted access to their software. MRP reports grants from HeartFlow, Johnson & Johnson, National Heart, Lung and Blood Institute, and Patient Centered Outcomes Research Institute and personal fees from Bayer Healthcare, Janssen, Novartis, and Medscape. RKA-L reports grant support from the British Heart Foundation; personal fees from Abbott Vascular, Fondazione Internazionale Menarini, Shockwave, Cathworks, Medtronic, Philips, and Servier Pharmaceuticals; and board participation for Janssen Pharmaceuticals and Cathworks. All other authors declare no competing interests.